<DOC>
	<DOCNO>NCT01777360</DOCNO>
	<brief_summary>To determine , patient present severe asthma increase bronchial smooth muscle mass , would best candidate bronchial THERMOPLASTY . THERMOPLASTY improve control asthma , reduce day-to-day symptom severe exacerbation , improve respiratory function</brief_summary>
	<brief_title>Bicentric Prospective Study , Evaluating Bronchial THERMOPLASTY Patient Presenting Severe Uncontrolled Asthma</brief_title>
	<detailed_description>Bicentric prospective study , evaluate bronchial THERMOPLASTY patient severe uncontrolled asthma significant bronchial smooth muscle mass . Primary Objective determine patient would best candidate bronchial THERMOPLASTY improve control asthma , reduce day-to-day symptom severe exacerbation , improve respiratory function . Primary Endpoint reduction smooth muscle surface area , objectify bronchial biopsy THERMOPLASTY patient present severe asthma secondary criterion : - number severe exacerbation ( oral corticosteroid , emergency room visit , hospitalization ) - time first exacerbation - respiratory function - control asthma ( ACQ - Asthma Control Questionnaire ) - quality life ( AQLQ - Asthma Quality Life Questionnaire ) - fraction exhale nitric oxide ( FENO ) - measurement thickness bronchial wall use tomodensitometry ( scan ) . The inclusion period 28 month limit maximum 80 subject . The actual number determine use two-stage stop method . An intermediate analysis carry follow evaluation statistical analysis 40 patient . - If primary endpoint p-value &lt; 0.0294 , success declare inclusion cease . - If p-value &gt; 0.0294 , additional patient recruit total 80 patient include assessed . At inclusion , sociodemographic data collect , number exacerbation per year , date fibroscopy , data asthma control ( ACQ ) , data quality life ( AQLQ ) , respiratory function ( EFR ) , fraction exhale nitric oxide ( FENO ) , thickness bronchial wall evaluate use scanner surface area smooth muscle bronchial sub-mucous layer evaluate . At 3 month post-THERMOPLASTY , data collect . One year THERMOPLASTY , number exacerbation , data asthma control ( ACQ ) , quality life ( AQLQ ) , respiratory function ( EFR ) , fraction exhale nitric oxide ( FENO ) , thickness bronchial wall possible complication collect .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<criteria>Aged 1875 year Patients severe asthma uncontrolled despite optimal treatment present least one exacerbation take oral corticosteroid within previous 12 month With variable bronchial obstruction ( FEV1 &gt; 30 &lt; 70 % theoretical ) Patients know severe asthma care Pneumology Department BICHAT Hospital Paris ( Prof. AUBIER ) Nord Hospital Marseilles ( Prof. CHANEZ ) . Covered French national health insurance . Patient severe exacerbation asthma require high dos oral corticosteroid ( &gt; 60 mg ) month inclusion . Patient exacerbation . Patient present severe exacerbation undesirable reaction relate bronchoscopy . Patient FEV1 &lt; 30 % theoretical take shortacting B2 mimetic . Patient oxygen saturation measure pulse oximetry &lt; 90 % ambient air . Patient present clinically significant electrocardiogram abnormality . Patient present uncontrolled comorbidity . Patient present coagulation platelet abnormality . Patient habitual contraindication bronchial endoscopy . Patient hemostasis disorder Presence pacemaker , internal defibrillator , implantable electronic device . Contraindication corticosteroid high dos atarax Pregnant woman lactate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>severe</keyword>
	<keyword>uncontrolled</keyword>
</DOC>